Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

September 15, 2018

Study Completion Date

November 2, 2018

Conditions
Gastric RetentionHealthy
Interventions
DRUG

Formulation A

Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

DRUG

Formulation B

Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

DRUG

Formulation C

Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

DRUG

Formulation D

Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

DRUG

Formulation E

Placebo Capsule containing microcrystalline cellulose

PROCEDURE

Endoscopy

Endoscopy at 2 hours post dosing

PROCEDURE

Magnetic Resonance Imaging

MRI will be performed on specified days according to protocol

Trial Locations (1)

5000

CMAX, Adelaide

All Listed Sponsors
lead

Lyndra Inc.

INDUSTRY